• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Lee Newcomer Addresses the Differences Between UnitedHealthcare and CMS' Payment Models

Video

Lee Newcomer, MD, MHA, private consultant, discusses the differences between UnitedHealthcare's pilot episodic payment model and CMS models.

Lee Newcomer, MD, MHA, private consultant, discusses the differences between UnitedHealthcare's pilot episodic payment model and CMS models.

Transcript

What are the differences between UnitedHealthcare’s pilot episodic payment model and CMS models?

Well, first and foremost this was a commercial population rather than Medicare. I think that’s critical because we used the drug margins as one of the ways to fund the episode payment. The margins are much smaller in Medicare because of the contractual rates that they pay.

Probably a second key difference is that, that model used a comparison group from the fee-for-service database. So [UnitedHealthcare] had been collecting clinical information on its commercial patients for almost 7 years. That allowed us to match patients in our pilot episode payment to the fee-for-service fairly exactly.

CMS just didn’t have that database yet but to their credit — they’re building it, and they will get there. But, in the first round they had to use a broader adjustment so rather than saying adjuvant breast cancer, it was just breast cancer. That’s an important difference because it does make the comparisons a lot more accurate to have the most accurate comparison database you can find.

How did UnitedHealthcare work with physician partners to utilize the results from the pilot episodic payment model?

Well the data is always fed back to the physician so we would have an annual meeting with them and bring the data back to them. What OCM I think is doing quite well —now that they have their systems worked out – is giving quarterly data back to the physicians so that they can use it to manage their processes. That’s important because timely data makes the chance of doing this successfully a lot better.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.